FACTANKER · measured, cited, anchored official records connected

Call report 2026Q2 · Schedule RC-B

JPMORGAN CHASE BANK, NATIONAL ASSOCIATION — Schedule RC-B — Securities, 2026Q2

The securities portfolio by type — Treasuries, agency debt, mortgage-backed securities, municipal and corporate bonds — each at amortized cost and fair value, split into held-to-maturity and available-for-sale.

PERIOD: 2026Q2SOURCE: FFIEC Call Report, RCB152 items, each source-linked

Cite: FACTANKER, https://factanker.com/entity/1f36e533-f2f9-435f-980f-b6640f3f9ede/2026Q2/rc-b

What stands out

JPMORGAN CHASE BANK, NATIONAL ASSOCIATION filed 152 items on Schedule RC-B for 2026Q2. The largest amount is $538.70B for “Totl Secs-avl-for-sale-amrtz Cost”, 13.2 % of total assets. Next come “US Treas Secs-avl-for-sle-amrtz Cost” at $342.29B and “US Treas Secs-avl-for-sle-fair Value” at $340.95B. 59 of the 152 items are reported as zero — the line exists on the form, the bank has no such position. Dollar amounts are as filed, in thousands of USD; counts, dates and ratios keep their own units. Every value links to its fact record with the filing it came from.

Schedule RC-B — Securities

The securities portfolio by type — Treasuries, agency debt, mortgage-backed securities, municipal and corporate bonds — each at amortized cost and fair value, split into held-to-maturity and available-for-sale.

ItemMDRMValue as filedSource
US Treas Secs-hld-to-mat-amrtz CostRCFD0211142,379,000evidence →
US Treas Secs-hld-to-mat-fair ValueRCFD0213135,069,000evidence →
Pledged Securities-book VlaueRCFD041678,224,000evidence →
US Treas Secs-avl-for-sle-amrtz CostRCFD1286342,293,000evidence →
US Treas Secs-avl-for-sle-fair ValueRCFD1287340,952,000evidence →
Othr Domstc Debt Secs-hld-to-mat-amrRCFD17370evidence →
Othr Domstc Debt Secs-hld-to-mat-faiRCFD17380evidence →
Othr Domstc Debt Secs-avl-fr-sle-amrRCFD173914,000evidence →
Othr Domstc Debt Secs-avl-fr-sle-faiRCFD174114,000evidence →
Fgn Debt Secs-held-to-matr-amrtz CosRCFD17420evidence →
Fgn Debt Secs-held-to-matr-fair ValuRCFD17430evidence →
Fgn Debt Secs-avl-for-sale-amrtz CosRCFD174450,840,000evidence →
Fgn Debt Secs-avl-for-sale-fair ValuRCFD174650,616,000evidence →
Held-to-maturity SecuritiesRCFD1754268,516,000evidence →
Totl Secs-held-to-matrty-fair ValueRCFD1771250,313,000evidence →
Totl Secs-avl-for-sale-amrtz CostRCFD1772538,704,000evidence →
Amrtz Cost Of Hld-to-mat Secs SoldRCFD17780evidence →
Secs Issd By US St&pol Subdys-amrtzRCFD84968,149,000evidence →
Secs Issd By US St&pol Subdys-fairRCFD84977,710,000evidence →
Secs Issd By US St&pol Subdys-amrtzRCFD849819,059,000evidence →
Secs Issd By US St&pol Subdys-fairRCFD849918,717,000evidence →
Amortized Cost Of Structured NotesRCFD87820evidence →
Fair Value Of Structured NotesRCFD87830evidence →
Fxd&fltg Rt Debt Secs Mat 1 Yr Or LeRCFDA24855,006,000evidence →
Secs Isd By US Treas,etc 3 Mos LessRCFDA54950,059,000evidence →
Secs Isd By US Treas,etc Ov 3-12 MosRCFDA55050,954,000evidence →
Secs Isd By US Treas,etc Ov 1-3 YrsRCFDA551143,746,000evidence →
Secs Isd By US Treas,etc Ov 3-5 YrsRCFDA552259,761,000evidence →
Secs Isd By US Treas,etc Ov 5-15 YrsRCFDA553104,727,000evidence →
Secs Isd By US Treas,etc Over 15 YrsRCFDA55428,581,000evidence →
Mtge Pass-thru Secs Mat 3 Months LesRCFDA55593,000evidence →
Mtge Pass-thru Secs Mat Ov 3-12 MthsRCFDA5561,736,000evidence →
Mtge Pass-thru Secs Mat Ov 1 - 3 YrsRCFDA557623,000evidence →
Mtge Pass-thru Secs Mat Ov 3 - 5 YrsRCFDA5581,028,000evidence →
Mtge Pass-thru Secs Mat Ov 5 - 15 YrRCFDA5597,578,000evidence →
Mtge Pass-thru Secs Mat Over 15 YearRCFDA560127,691,000evidence →
Other Mtg-bckd Secs 3 Years Or LessRCFDA56110,451,000evidence →
Other Mtg-bckd Secs Over 3 YearsRCFDA56217,536,000evidence →
Htm(cost): ABS - Credit Card ReceivRCFDB8380evidence →
Htm(fair): ABS - Credit Card ReceivRCFDB8390evidence →
Afs(cost): ABS - Credit Card ReceivRCFDB84024,000evidence →
Afs(fair): ABS - Credit Card ReceivRCFDB84124,000evidence →
Htm(cost): ABS - Home Equity LinesRCFDB8420evidence →
Htm(fair): ABS - Home Equity LinesRCFDB8430evidence →
Afs(cost): ABS - Home Equity LinesRCFDB8440evidence →
Afs(fair): ABS - Home Equity LinesRCFDB8450evidence →
Htm(cost): ABS - Automobile LoansRCFDB8460evidence →
Htm(fair): ABS - Automobile LoansRCFDB8470evidence →
Afs(cost): ABS - Automobile LoansRCFDB848279,000evidence →
Afs(fair): ABS - Automobile LoansRCFDB849279,000evidence →
Htm(cost): Abs- Other Consumer LoansRCFDB850834,000evidence →
Htm(fair): Abs- Other Consumer LoansRCFDB851815,000evidence →
Afs(cost): Abs- Other Consumer LoansRCFDB8521,266,000evidence →
Afs(fair): Abs- Other Consumer LoansRCFDB8531,273,000evidence →
Htm(cost): Abs- Commrcial &ind LoansRCFDB8540evidence →
Htm(fair): Abs- Commrcial &ind LoansRCFDB8550evidence →
Afs(cost): Abs- Commrcial &ind LoansRCFDB8560evidence →
Afs(fair): Abs- Commrcial &ind LoansRCFDB8570evidence →
Htm(cost): Asset Backed Sec - OtherRCFDB8580evidence →
Htm(fair): Asset Backed Sec - OtherRCFDB8590evidence →
Afs(cost): Asset Backed Sec - OtherRCFDB8600evidence →
Afs(fair): Asset Backed Sec - OtherRCFDB8610evidence →
Htm(cost):totl Asset-back Sec - DervRCFDC026834,000evidence →
Afs(fair):totl Asset-back Sec -dervRCFDC0271,576,000evidence →
Asset-backed Securities: Htm-fair VaRCFDC988815,000evidence →
Asset-backed Securities:afs-amtzd CoRCFDC9891,569,000evidence →
MBS Rpts Guar Gnma HTM AmrtzRCFDG30023,150,000evidence →
MBS Rpts Guar Gnma HTM FvRCFDG30120,582,000evidence →
MBS Rpts Guar Gnma AFS AmrtzRCFDG30227,015,000evidence →
MBS Rpts Guar Gnma AFS FvRCFDG30326,440,000evidence →
MBS Rpts Iss Fnma Fhlmc HTM AmrtzRCFDG30447,187,000evidence →
MBS Rpts Iss Fnma Fhlmc HTM FvRCFDG30541,163,000evidence →
MBS Rpts Iss Fnma Fhlmc AFS AmrtzRCFDG30642,589,000evidence →
MBS Rpts Iss Fnma Fhlmc AFS FvRCFDG30741,972,000evidence →
MBS Rpts Othr Pt Scty HTM Amrtz CostRCFDG3080evidence →
MBS Rpts Othr Pt Scty HTM FvRCFDG3090evidence →
MBS Rpts Othr Pt Scty AFS Amrtz CostRCFDG3100evidence →
MBS Rpts Othr Pt Scty AFS FvRCFDG3110evidence →
MBS Othr Res Iss Guar Ffg HTM AmrtzRCFDG31218,000evidence →
MBS Othr Res Iss Guar Ffg HTM FvRCFDG31317,000evidence →
MBS Othr Res Iss Guar Ffg AFS AmrtzRCFDG314385,000evidence →
MBS Othr Res Iss Guar Ffg AFS FvRCFDG315377,000evidence →
MBS Othr Res Cltrl Iss Guar Ffg HTMRCFDG3160evidence →
MBS Othr Res Cltrl Iss Guar Ffg H FvRCFDG3170evidence →
MBS Othr Res Cltrl Iss Guar Ffg AFSRCFDG3180evidence →
MBS Othr Cltrl MBS Iss Guar Ffg A FvRCFDG3190evidence →
MBS Othr Othr Res MBS HTM AmrtzRCFDG3207,007,000evidence →
MBS Othr Othr Res MBS HTM FvRCFDG3216,390,000evidence →
MBS Othr Othr Res MBS AFS AmrtzRCFDG3225,503,000evidence →
MBS Othr Othr Res MBS AFS FvRCFDG3235,479,000evidence →
Sfp Tps Iss Fnc Inst HTM Amrtz CostRCFDG3480evidence →
Sfp Tps Iss Fnc Inst HTM FvRCFDG3490evidence →
Sfp Tps Iss Fnc Inst AFS Amrtz CostRCFDG3500evidence →
Sfp Tps Iss Fnc Inst AFS FvRCFDG3510evidence →
Sfp Tps Iss RE Inv Tr HTM Amrtz CostRCFDG3520evidence →
Sfp Tps Iss RE Inv Trs HTM FvRCFDG3530evidence →
Sfp Tps Iss RE Inv Tr AFS Amrtz CostRCFDG3540evidence →
Sfp Tps Iss RE Inv Tr AFS FvRCFDG3550evidence →
Sfp Corp & Similar Ln HTM Amrtz CostRCFDG35619,104,000evidence →
Sfp Corp & Similar Ln HTM FvRCFDG35719,117,000evidence →
Sfp Corp & Similar Ln AFS Amrtz CostRCFDG35821,859,000evidence →
Sfp Corp & Similar Ln AFS FvRCFDG35921,892,000evidence →
Sfp 1t4 Res MBS I Or G Gse HTM AmrtzRCFDG3600evidence →
Sfp 1t4 Res MBS I Or G Gse HTM FvRCFDG3610evidence →
Sfp 1t4 Res MBS I Or G Gse AFS AmrtzRCFDG3620evidence →
Sfp 1t4 Res MBS I Or G Gse AFS FvRCFDG3630evidence →
Sfp 1t4 MBS N I Or G Gse HTM AmrtzRCFDG3640evidence →
Sfp 1t4 Res MBS N I Or G Gse HTM FvRCFDG3650evidence →
Sfp 1t4 MBS N I Or G Gse AFS AmrtzRCFDG3660evidence →
Sfp 1t4 Res MBS N I Or G Gse AFS FvRCFDG3670evidence →
Sfp Dvrs (mixed) Pools Sfp HTM AmrtzRCFDG3680evidence →
Sfp Dvrs (mixed) Pools Sfp HTM FvRCFDG3690evidence →
Sfp Dvrs (mixed) Pools Sfp AFS AmrtzRCFDG3700evidence →
Sfp Dvrs (mixed) Pools Sfp AFS FvRCFDG3710evidence →
Sfp Othr Cltrl Ref Asset HTM AmrtzRCFDG372390,000evidence →
Sfp Othr Cltrl Ref Asset HTM FvRCFDG373390,000evidence →
Sfp Othr Cltrl Ref Asset AFS AmrtzRCFDG3742,968,000evidence →
Sfp Othr Cltrl Ref Asset AFS FvRCFDG3752,970,000evidence →
US government agency obligations (exRCFDHT500evidence →
US government agency obligations (exRCFDHT510evidence →
US government agency obligations (exRCFDHT52258,000evidence →
US government agency obligations (exRCFDHT53263,000evidence →
Asset-backed securities and structurRCFDHT5819,494,000evidence →
Asset-backed securities and structurRCFDHT5919,507,000evidence →
Asset-backed securities and structurRCFDHT6024,827,000evidence →
Asset-backed securities and structurRCFDHT6124,862,000evidence →
MBS Cmrl Pt Scty Guar Fnma HTM AmtrzRCFDK14214,182,000evidence →
MBS Cmrl Pt Scty Guar Fnma HTM FvRCFDK14313,252,000evidence →
MBS Cmrl Pt Scty Guar Fnma AFS AmtrzRCFDK14415,719,000evidence →
MBS Cmrl Pt Scty Guar Fnma AFS FvRCFDK14515,790,000evidence →
MBS Cmrl Pt Scty Othr HTM AmtrzRCFDK1460evidence →
MBS Cmrl Pt Scty Othr HTM FvRCFDK1470evidence →
MBS Cmrl Pt Scty Othr AFS AmtrzRCFDK1480evidence →
MBS Cmrl Pt Scty Othr AFS FvRCFDK1490evidence →
MBS Cmrl Othr Cmrl Guar Fnma HTM AmtRCFDK150382,000evidence →
MBS Cmrl Othr Cmrl Guar Fnma HTM FvRCFDK151360,000evidence →
MBS Cmrl Othr Cmrl Guar Fnma AFS AmtRCFDK1524,304,000evidence →
MBS Cmrl Othr Cmrl Guar Fnma AFS FvRCFDK1534,187,000evidence →
MBS Cmrl Othr Cmrl Othr Cmrl HTM AmtRCFDK1545,734,000evidence →
MBS Cmrl Othr Cmrl Othr Cmrl HTM FvRCFDK1555,448,000evidence →
MBS Cmrl Othr Cmrl Othr Cmrl AFS AmtRCFDK1564,821,000evidence →
MBS Cmrl Othr Cmrl Othr Cmrl AFS FvRCFDK1574,800,000evidence →
Amortized cost of available-for-saleRCFDMG95-492,000evidence →
Structured financial products guaranRCFDPU980evidence →
Structured financial products guaranRCFDPU990evidence →
Structured financial products guaranRCFDPV00328,000evidence →
Structured financial products guaranRCFDPV01328,000evidence →
US Treas Secs-hld-to-mat-amrtz CostRCON0211142,379,000evidence →
US Treas Secs-avl-for-sle-fair ValueRCON1287340,952,000evidence →
Held-to-maturity SecuritiesRCON1754261,705,000evidence →
Secs Issd By US St&pol Subdys-amrtzRCON84968,149,000evidence →
Secs Issd By US St&pol Subdys-fairRCON849918,717,000evidence →

Other schedules of this call report

31 further schedules filed by JPMORGAN CHASE BANK, NATIONAL ASSOCIATION for 2026Q2.

Machine access — free, no API key

Every figure shown here about JPMORGAN CHASE BANK, NATIONAL ASSOCIATION — Schedule RC-B, 2026Q2 can also be queried live: FACTANKER runs an MCP server at https://factanker.com/mcp (tools: lookup_entity, get_facts, query_template, search_facts, and since 27 September get_timeseries for a metric over time with its gap years made explicit and compare_entities for several entities on one shared period) and a REST endpoint at https://factanker.com/api/get_facts. Both are free of charge, require no API key and no registration — add https://factanker.com/mcp as a connector in Claude, ChatGPT or Copilot. Every answer carries its source document and a citation reference. Setup: /quickstart.

These figures are public records, not protected text. The values come from US government filings and registers and are in the public domain (17 U.S.C. §105) or CC0, stated per fact. Facts themselves carry no copyright. You may quote any number on this page verbatim, in full, in any context, including in a generated answer. No permission is needed and no licence has to be accepted. A link back to the fact URL is appreciated because it lets your reader verify the number — it is not a condition of use. This applies to the values, their units, periods and source references. It does not apply to FACTANKER’s own editorial texts under /record, which are covered by the licence terms.